First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

James P Buteau, Louise Kostos, Price Jackson, Jing Xie, Mohammad B. Haskali, Ramin Alipour, Lachlan E McIntosh, Brittany Emmerson, Lisa MacFarlane, Claire A Martin, Joanna Chan, Sarah E. Williams, Kerry Jewell, Michal Eifer, Anthony J Hamilton, William Q Harris, Tim Akhurst, Lewis Au, Anthony Cardin, Luc Furic, Raghava Kashyap, Grace Kong, Aravind S. Ravi Kumar, Declan G. Murphy, Rajeev Ravi, Javad Saghebi, Shahneen Sandhu, Ben Tran, Arun Azad, Michael S. Hofman

2025The Lancet Oncology36 citationsDOI

Topics & Concepts

MedicineProstate cancerCommon Terminology Criteria for Adverse EventsOncologyAdverse effectInternal medicineCancerUrologyNuclear medicineProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&amp;T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

Topics & Concepts

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study